33 Biotechnology Stocks to Sell Now

33 Biotechnology Stocks to Sell Now

This week, the ratings of 33 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

BioMarin Pharmaceutical Inc. (BMRN) earns a F this week, moving down from last week’s grade of D. BioMarin Pharmaceutical Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

Slipping from a D to a F rating, Gilead Sciences, Inc. (GILD) takes a hit this week. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of GILD stock.

Emergent BioSolutions Inc. (EBS) is having a tough week. The company’s rating falls from a C to a D. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of EBS stock.

Cellectis SA Sponsored ADR (CLLS) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

Myriad Genetics, Inc. (MYGN) experiences a ratings drop this week, going from last week’s C to a D. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of MYGN stock.

Heron Therapeutics Inc (HRTX) declines this week from a D to a F. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

This is a rough week for FibroGen, Inc. (FGEN). The company’s rating falls to D from the previous week’s C. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

This week, Flexion Therapeutics, Inc. (FLXN) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

Clovis Oncology, Inc. (CLVS) slips from a D to a F this week. Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLVS stock.

This week, Seres Therapeutics Inc’s (MCRB) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MCRB stock.

Concert Pharmaceuticals, Inc.’s (CNCE) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

Natera, Inc. (NTRA) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NTRA stock.

Aquinox Pharmaceuticals, Inc.’s (AQXP) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AQXP stock.

This week, Pfenex, Inc. (PFNX) drops from a D to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Slipping from a B to a D rating, Enzymotec Ltd. (ENZY) takes a hit this week. The company also gets F’s in sales growth, earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

This week, Stemline Therapeutics, Inc.’s (STML) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of STML stock.

Novavax, Inc. (NVAX) experiences a ratings drop this week, going from last week’s D to a F. Novavax, Inc. creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVAX stock.

Immune Design Corp. (IMDZ) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

Vital Therapies, Inc. (VTL) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Spectrum Pharmaceuticals, Inc. (SPPI) gets weaker ratings this week as last week’s C drops to a D. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

Mirati Therapeutics Inc. (MRTX) declines this week from a D to a F. Mirati Therapeutics Inc. engages in the development of therapeutics for the treatment of cancer. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

This is a rough week for Sangamo BioSciences, Inc. (SGMO). The company’s rating falls to F from the previous week’s D. Sangamo BioSciences, Inc. is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

This week, Keryx Biopharmaceuticals, Inc.’s (KERX) rating worsens to a D from the company’s C rating a week ago. Keryx Biopharmaceuticals, Inc. focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of KERX stock.

Onconova Therapeutics Inc. (ONTX) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONTX stock.

Slipping from a D to a F rating, Regulus Therapeutics Inc. (RGLS) takes a hit this week. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Array BioPharma Inc.’s (ARRY) rating weakens this week, dropping to a F versus last week’s D. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company also gets F’s in sales growth, earnings growth, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

This is a rough week for Stellar Biotechnologies, Inc. (SBOT). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

Conatus Pharmaceuticals Inc. (CNAT) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

This week, OncoSec Medical Incorporated (ONCS) drops from a D to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONCS stock.

Actinium Pharmaceuticals, Inc. (ATNM) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATNM stock.

ArQule, Inc. (ARQL) gets weaker ratings this week as last week’s C drops to a D. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

Catalyst Biosciences, Inc. (CBIO) experiences a ratings drop this week, going from last week’s C to a F. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBIO stock.

Cerulean Pharma, Inc. (CERU) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CERU stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/33-biotechnology-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC